Safety · source year
5 selected, source-linked safety and enforcement records dated 2021. This is selective source coverage, not a complete timeline.
5 selected records.
4 connected profiles.
5 distinct public records.
Cited chronology
Dulaglutide
FDA's dated enforcement report D-0773-2021 lists Class II and source status Terminated for Eli Lilly & Company. PeptideScanner connects the report to reviewed application BLA125469 through exact openFDA application-number annotations.
Linaclotide
FDA's dated enforcement report D-0417-2021 lists Class II and source status Terminated for Cardinal Health Inc. PeptideScanner connects the report to reviewed application NDA202811 through exact openFDA application-number annotations.
Semaglutide
FDA's dated enforcement report D-0536-2021 lists Class II and source status Terminated for Cardinal Health Inc. PeptideScanner connects the report to reviewed application NDA213051 through exact openFDA application-number annotations.
Liraglutide
FDA's dated enforcement report D-0618-2021 lists Class II and source status Terminated for Novo Nordisk Inc. PeptideScanner connects the report to reviewed application NDA206321 through exact openFDA application-number annotations.
Liraglutide
FDA's dated enforcement report D-0622-2021 lists Class II and source status Terminated for Novo Nordisk Inc. PeptideScanner connects the report to reviewed application NDA022341 through exact openFDA application-number annotations.